Otsuka Pharmaceutical Co., Ltd.June 17, 2025

FDA 483 - Otsuka Pharmaceutical Co., Ltd. - June 17, 2025

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Otsuka Pharmaceutical Co., Ltd.

Record Details

An FDA inspection of Otsuka Pharmaceutical Co., Ltd. in Naka-Gun, Tokushima, Japan, a sterile drug product manufacturer, revealed significant deficiencies. The firm failed to establish adequate written procedures for production and process controls, particularly concerning aseptic processing validation and environmental monitoring. Additionally, laboratory controls for growth promotion testing were found to be deficient.

Company: Otsuka Pharmaceutical Co., Ltd.
Inspection Date: June 17, 2025
Product Type: Drugs
Office: Office of Inspections and Investigations
Person: Bijoy Panicker

Open in Dashboard

ID · 500e2ebb-23c6-432a-a86f-6865269ae086